India's Central Drugs Standard Control Organisation (CDSCO) says Pfizer officials failed to turn up to meetings after the company's application was made in early December

Oxfam's 'The Inequality Virus' report said it would take an unskilled worker 10,000 years to make what businessman Mukesh Ambani made in an hour during the pandemic and three years to make what he made in a second

Japan's Nikkei 225 rose 0.8% to finish at 28,756.86, while South Korea's Kospi edged up 1.5% to 3,160.84. Hong Kong's Hang Seng slipped 0.1% to 29,927.76, while the Shanghai Composite added 1.1% to 3,621.26

The pandemic has brought a realisation that we need greater public health infrastructure so that we are ready for any calamity of this order in the future

Being prudent, adhering to strong governance practices and focusing on long-term growth are critical

Banks provide the lifeblood to the financial well-being of different segments. In a crisis, wehave to do everything to safeguard their interests

COVID-19 vaccination Day 2: 2.25 lakh inoculated; 447 adverse events reported A total of 2,24,301 beneficiaries have been inoculated with COVID-19 vaccine so far, out of which only 447 adverse events following immunisation (AEFI) were reported, the Union Health Ministry said on day two of the nationwide vaccination drive on Sunday. Out of the 447 adverse events following immunisation, only three required hospitalisation. India has approved two vaccines -- Covaxin developed by Bharat Biotech...

Key to the success of the pan-India COVID-19 vaccination drive, scheduled to be launched by PM Narendra Modi on January 16, will be the cybersecurity framework India has readied, experts say

Moderna CEO Stephane Bancel has warned that the novel coronavirus might never disappear and there are high chances of it becoming an endemic disease

Except for pharma, realty and financial services, all other indices on NSE closed in green territory, with over 3% gain registered in PSU banking sector

A team from Precisa Medicamentos visited the Bharat Biotech's Hyderabad facility last week to discuss potential export possibilities of Covaxin with Chairman Dr Krishna Ella on the January 7-8

Full authorisation-better known as \"full pre-qualification\"-is a pre-requisite to sell the vaccine in the open market or for mass immunisation of healthy individuals who are not frontline workers

While large companies and organisations have the capital and the resources to deploy various technologies and solutions, on an individual level, the threat looms large

Cyber security is becoming big business. Here's why

(For) all our vaccines, we are looking at right now..(we) are targeting 2-8 degree because our logistics are worked out on that basis and we are working on that, DBT secretary Renu Swarup said at a press briefing

This daunting challenge is not only for India but also for all the governments across the globe as they start inoculating their populations to tackle the pandemic, noted Dr Soumya Swaminathan, Chief Scientist of WHO

The statement came shortly after Adar Poonawala, CEO, Serum Institute tweeted that a public statement would be issued to clear up any miscommunication between the two companies

It's great to see India's leadership in scientific innovation and vaccine manufacturing capability as the world works to end the COVID-19 pandemic, tweets the billionaire philanthropist

COVID-19 vaccine update: India has approved two coronavirus vaccines for emergency use - Bharat Biotech-ICMR's Covaxin and Covishield manufactured by Pune's Serum Institute

Without naming Serum Institute CEO Adar Poonawalla, who had termed vaccines other than that of Pfizer, Moderna and Oxford-AstraZeneca as 'just like water', Krishna Ella said, 'We do 200 per cent honest clinical trials and yet we receive backlash'